You are now leaving XTANDI.com
The website you are about to visit is not owned or controlled by Astellas. Astellas are not responsible for the information or services on this site.
Over the last decade there have been tremendous advances in the field of oncology, but there are still patients that need more options for hard-to-treat cancers. During the 2021 American Society of Oncology (ASCO) Annual Meeting, Astellas Oncology will present data across our portfolio of therapies that help to advance our commitment to changing the course for patients with bladder, acute myeloid leukemia (AML), prostate and gastric gastroesophageal junction (GEJ) cancers.
Learn more about our portfolio, as well as the ambitious thinking and spirited collaboration that drives our work at www.astellasoncology.com.
May 19, 2021Astellas and Seagen Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy
Caregivers often play the essential role of supporter throughout the emotional rollercoaster of a cancer diagnosis, accompanying those with cancer through treatment and beyond. Find out just how powerful this role can be:
This website is intended for U.S. residents only. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including those under development. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.